{"id":"artemether-lumefantrine-al","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"},{"rate":"3-8","effect":"Vomiting"},{"rate":"3-8","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"3-7","effect":"Dizziness"},{"rate":"1-3","effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artemether, a semi-synthetic artemisinin derivative, rapidly kills early-stage malaria parasites by generating reactive oxygen species that damage parasite proteins and DNA. Lumefantrine, a long-acting antimalarial, inhibits parasite heme polymerization and prevents the formation of hemozoin crystals, leading to parasite death. Together, they provide rapid parasite clearance and sustained suppression of parasitemia.","oneSentence":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:36.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi"},{"name":"Malaria treatment in endemic regions"}]},"trialDetails":[{"nctId":"NCT06967519","phase":"PHASE4","title":"OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-18","conditions":"Malaria, Hiv","enrollment":380},{"nctId":"NCT05567016","phase":"NA","title":"CHILD (Child Health and Infection With Low Density) Malaria","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-07-18","conditions":"Malaria,Falciparum, Malaria","enrollment":600},{"nctId":"NCT07362498","phase":"","title":"Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya","status":"COMPLETED","sponsor":"Strathmore University","startDate":"2020-06-01","conditions":"Malaria Falciparum","enrollment":316},{"nctId":"NCT07358767","phase":"NA","title":"Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women","status":"COMPLETED","sponsor":"Noguchi Memorial Institute for Medical Research","startDate":"2021-07-01","conditions":"Malaria","enrollment":3300},{"nctId":"NCT05757167","phase":"PHASE4","title":"Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics","status":"RECRUITING","sponsor":"Duke University","startDate":"2023-11-06","conditions":"Malaria,Falciparum, Malaria in Pregnancy, Malaria in Childbirth","enrollment":2500},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1680},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":"Malaria","enrollment":870},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax Malaria","enrollment":606},{"nctId":"NCT06970600","phase":"NA","title":"Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2024-03-07","conditions":"Malaria (Uncomplicated)","enrollment":352},{"nctId":"NCT06516042","phase":"PHASE3","title":"Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"PATH","startDate":"2024-08-21","conditions":"Plasmodium Falciparum, Malaria","enrollment":10350},{"nctId":"NCT03453840","phase":"PHASE4","title":"Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-02-21","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":305},{"nctId":"NCT06347471","phase":"PHASE4","title":"The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy","status":"RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-05-28","conditions":"Falciparum; Malaria","enrollment":120},{"nctId":"NCT05764746","phase":"PHASE2, PHASE3","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2023-05-01","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":384},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT04079621","phase":"PHASE4","title":"Short Course Radical Cure of P. Vivax Malaria in Nepal","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2021-10-27","conditions":"Malaria, Malaria, Vivax, Malaria,Falciparum","enrollment":27},{"nctId":"NCT04280692","phase":"PHASE1, PHASE2","title":"Controlled Human Malaria Infection Transmission Model - Phase A","status":"SUSPENDED","sponsor":"University of Oxford","startDate":"2022-08-22","conditions":"Malaria,Falciparum","enrollment":44},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":"Plasmodium Falciparum, Malaria, Uncomplicated Malaria","enrollment":352},{"nctId":"NCT04041973","phase":"NA","title":"Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-03-11","conditions":"Malaria","enrollment":1480},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT04695197","phase":"PHASE3","title":"Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-01-08","conditions":"Covid-19, Malaria","enrollment":143},{"nctId":"NCT04767191","phase":"PHASE4","title":"Malaria Therapeutic Efficacy Study (TES) Kenya","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2021-03-15","conditions":"Uncomplicated Malaria","enrollment":400},{"nctId":"NCT04147546","phase":"PHASE3","title":"Additional Screening With Sensitives RDTs and Malaria","status":"COMPLETED","sponsor":"Institut de Recherche en Sciences de la Sante, Burkina Faso","startDate":"2020-08-31","conditions":"Plasmodium Falciparum Malaria, Malaria Diagnosis","enrollment":340},{"nctId":"NCT03355664","phase":"PHASE3","title":"Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-03-19","conditions":"Malaria, Falciparum","enrollment":310},{"nctId":"NCT05192265","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":"Malaria Fever, Plasmodium Falciparum Malaria, Uncomplicated Malaria","enrollment":172},{"nctId":"NCT04053907","phase":"NA","title":"P. Falciparum Infection Dynamics and Transmission to Inform Elimination","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-08-15","conditions":"Malaria","enrollment":4000},{"nctId":"NCT05081089","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-12","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Malaria","enrollment":1272},{"nctId":"NCT05060198","phase":"NA","title":"Therapeutic Efficacy Study of AL and DP in Western Kenya","status":"COMPLETED","sponsor":"Kenya Medical Research Institute","startDate":"2016-06-17","conditions":"Malaria,Falciparum","enrollment":340},{"nctId":"NCT04416945","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-09-20","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":31443},{"nctId":"NCT03510481","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-14","conditions":"Malaria","enrollment":478},{"nctId":"NCT04456634","phase":"PHASE1","title":"Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2020-09-10","conditions":"Malaria","enrollment":8},{"nctId":"NCT00297882","phase":"PHASE3","title":"Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2006-07","conditions":"Malaria","enrollment":816},{"nctId":"NCT04829695","phase":"PHASE4","title":"Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon","status":"UNKNOWN","sponsor":"University of Yaounde 1","startDate":"2021-04-05","conditions":"Falciparum Malaria","enrollment":184},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":"Malaria, Burkina Faso","enrollment":1050},{"nctId":"NCT03783299","phase":"PHASE4","title":"Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-11-28","conditions":"Plasmodium Falciparum Malaria","enrollment":39968},{"nctId":"NCT02654912","phase":"PHASE4","title":"Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration","status":"COMPLETED","sponsor":"PATH","startDate":"2016-02","conditions":"Malaria","enrollment":8682},{"nctId":"NCT04094727","phase":"PHASE4","title":"Malaria High-Risk Populations in Namibia","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-10-31","conditions":"Malaria","enrollment":3302},{"nctId":"NCT04531072","phase":"PHASE4","title":"Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine","status":"COMPLETED","sponsor":"Fogarty International Center of the National Institute of Health","startDate":"2018-09-18","conditions":"Drug Interaction","enrollment":20},{"nctId":"NCT04241705","phase":"NA","title":"Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia","status":"UNKNOWN","sponsor":"Armauer Hansen Research Institute, Ethiopia","startDate":"2020-01-20","conditions":"Malaria","enrollment":48960},{"nctId":"NCT04203186","phase":"NA","title":"A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)","status":"WITHDRAWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2020-03","conditions":"Plasmodium Falciparum","enrollment":""},{"nctId":"NCT04370977","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2018-03-21","conditions":"Malaria","enrollment":630},{"nctId":"NCT03705624","phase":"NA","title":"P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-08-06","conditions":"Malaria","enrollment":907},{"nctId":"NCT03764527","phase":"PHASE4","title":"Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2002-11-01","conditions":"Plasmodium Falciparum Malaria","enrollment":408},{"nctId":"NCT01967472","phase":"NA","title":"Adherence to Antimalarial Drugs in Sierra Leone","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-09-16","conditions":"Malaria","enrollment":1145},{"nctId":"NCT03387631","phase":"","title":"Efficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland Tanzania","status":"COMPLETED","sponsor":"National Institute for Medical Research, Tanzania","startDate":"2016-04","conditions":"Uncomplicated Malaria","enrollment":344},{"nctId":"NCT02184637","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-31","conditions":"Malaria, Vivax","enrollment":120},{"nctId":"NCT01976780","phase":"PHASE4","title":"In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy","status":"COMPLETED","sponsor":"Global Emerging Infections Surveillance and Response System","startDate":"2013-06","conditions":"Malaria","enrollment":118},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT02741024","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-10","conditions":"Malaria","enrollment":288},{"nctId":"NCT00852423","phase":"PHASE3","title":"Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2010-06","conditions":"Malaria in Pregnancy","enrollment":3428},{"nctId":"NCT02174900","phase":"PHASE2, PHASE3","title":"Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2014-10","conditions":"Malaria","enrollment":70},{"nctId":"NCT02662855","phase":"PHASE2","title":"Efficacy of Favipiravir Against Severe Ebola Virus Disease","status":"COMPLETED","sponsor":"Beijing Institute of Pharmacology and Toxicology","startDate":"2014-11","conditions":"Ebola Virus Disease","enrollment":77},{"nctId":"NCT02637128","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-03","conditions":"MALARIA, FALCIPARUM","enrollment":452},{"nctId":"NCT02325180","phase":"PHASE4","title":"Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2015-01","conditions":"Malaria, Falciparum","enrollment":338},{"nctId":"NCT00808951","phase":"PHASE4","title":"In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-12","conditions":"Malaria","enrollment":440},{"nctId":"NCT01697787","phase":"PHASE4","title":"Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2012-10","conditions":"Malaria","enrollment":150},{"nctId":"NCT01017770","phase":"PHASE4","title":"Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-09","conditions":"Uncomplicated P. Falciparum Malaria in Children","enrollment":340},{"nctId":"NCT02168569","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2011-06","conditions":"Malaria","enrollment":700},{"nctId":"NCT01944189","phase":"PHASE4","title":"Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2013-09","conditions":"Malaria, Falciparum","enrollment":70},{"nctId":"NCT01728961","phase":"PHASE4","title":"Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy","status":"TERMINATED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2012-02","conditions":"HIV Infection, Malaria","enrollment":19},{"nctId":"NCT00393679","phase":"PHASE3","title":"Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2007-07","conditions":"Fever, Malaria","enrollment":4112},{"nctId":"NCT01939886","phase":"PHASE3","title":"Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-04","conditions":"Malaria","enrollment":219},{"nctId":"NCT01603251","phase":"PHASE1, PHASE2","title":"Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-01","conditions":"Malaria","enrollment":120},{"nctId":"NCT00885287","phase":"PHASE4","title":"Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2009-07","conditions":"Malaria, Falciparum, HIV Infections","enrollment":830},{"nctId":"NCT01449045","phase":"PHASE3","title":"Trial of Malaria Seasonal IPTc Combined With Community Case Management","status":"COMPLETED","sponsor":"Cheikh Anta Diop University, Senegal","startDate":"2011-07","conditions":"Malaria","enrollment":4554},{"nctId":"NCT01567423","phase":"NA","title":"Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Epicentre","startDate":"2008-04","conditions":"Malaria, Falciparum","enrollment":301},{"nctId":"NCT01459146","phase":"PHASE4","title":"Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana","status":"UNKNOWN","sponsor":"Navrongo Health Research Centre, Ghana","startDate":"2010-12","conditions":"Malaria, Schistosomiasis, Helminthiasis","enrollment":345},{"nctId":"NCT01065116","phase":"PHASE3","title":"Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs","status":"COMPLETED","sponsor":"Malaria Consortium, Uganda","startDate":"2010-03","conditions":"Malaria","enrollment":920},{"nctId":"NCT00868465","phase":"NA","title":"Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-04","conditions":"Uncomplicated Malaria","enrollment":600},{"nctId":"NCT00902811","phase":"PHASE4","title":"Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2008-12","conditions":"Uncomplicated Falciparum Malaria","enrollment":600},{"nctId":"NCT00440752","phase":"","title":"The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance","status":"COMPLETED","sponsor":"Tropical Medicine Research Institute","startDate":"2006-10","conditions":"Falciparum Malaria, Antimalarials","enrollment":100},{"nctId":"NCT00374205","phase":"PHASE4","title":"Randomized Trial on Effectiveness of ACTs in Ghana","status":"TERMINATED","sponsor":"Bernhard Nocht Institute for Tropical Medicine","startDate":"2006-09","conditions":"Malaria, Falciparum","enrollment":245}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AL","Coartem"],"phase":"marketed","status":"active","brandName":"Artemether+Lumefantrine (AL)","genericName":"Artemether+Lumefantrine (AL)","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage. Used for Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, Malaria treatment in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}